InMode (INMD) Projected to Announce Earnings on Wednesday

Key Points

• InMode is expected to report Q3 2026 results before the market opens Wednesday, November 11. Analysts forecast earnings of $0.322 per share and revenue of $91.58 million.
• In its most recent quarter, InMode reported EPS of $0.35, matching estimates, and revenue of $95.59 million, above consensus; EPS was down from $0.47 a year earlier.
• Analysts’ consensus rating is Hold, with a $16 average price target. The stock recently traded at $14.08, and Weiss Ratings downgraded its rating to “sell.”

InMode (NASDAQ:INMD - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect InMode to announce earnings of $0.3220 per share and revenue of $91.58 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

InMode (NASDAQ:INMD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, hitting analysts' consensus estimates of $0.35. InMode had a net margin of 20.69% and a return on equity of 11.99%. The business had revenue of $95.59 million during the quarter, compared to the consensus estimate of $94.89 million. During the same quarter in the previous year, the firm posted $0.47 EPS. The firm's revenue was up .0% on a year-over-year basis.

InMode Stock Up 2.8%

NASDAQ INMD opened at $14.08 on Wednesday. InMode has a 52 week low of $12.72 and a 52 week high of $16.67. The firm has a market capitalization of $809.32 million, a P/E ratio of 10.96 and a beta of 1.98. The company has a 50-day moving average price of $14.33 and a 200-day moving average price of $14.32.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded InMode from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $16.00.

About InMode

InMode Ltd. NASDAQ: INMD is a global medical technology company that develops and commercializes energy-based platforms for aesthetic and medical treatments. Its systems are designed to support minimally invasive and noninvasive procedures performed by physicians and other healthcare professionals.

The company's product portfolio includes platforms and handpieces used in facial and body contouring, skin resurfacing, skin tightening, hair removal, and women's health applications. Its technologies include radio-frequency and other energy-based treatments, with products such as Morpheus8, BodyTite, FaceTite, Optimas, and EmpowerRF serving a range of clinical and aesthetic needs.

Founded in 2008, InMode sells its products through direct sales and distribution channels to medical practices, clinics, and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.